Mediastinal germ cell tumor
diseaseOn this page
Also known as germ cell neoplasm of mediastinumgerm cell neoplasm of the mediastinumgerm cell tumor of mediastinumgerm cell tumor of the mediastinumgerm cell tumour of mediastinumgerm cell tumour of the mediastinummediastinal germ cell neoplasmmediastinum germ cell tumormediastinum germ cell tumourthymic germ cell tumorthymic germ cell tumour
Summary
Mediastinal germ cell tumor (MONDO:0021067) is a cancer with 9 cohort genes (2 CIViC-evidence somatic drivers; 9 ClinVar predisposition records).
At a glance
- Classification: Cancer
- Cohort genes: 9
- ClinVar variants: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mediastinal germ cell tumor |
| Mondo ID | MONDO:0021067 |
| NCIT | C6437 |
| UMLS | C1334655 |
| MedGen | 233678 |
| GARD | 0025285 |
| Anatomy (UBERON) | UBERON:0003728 |
| Is cancer (heuristic) | yes |
Also known as: germ cell neoplasm of mediastinum · germ cell neoplasm of the mediastinum · germ cell tumor of mediastinum · germ cell tumor of the mediastinum · germ cell tumour of mediastinum · germ cell tumour of the mediastinum · mediastinal germ cell neoplasm · mediastinal germ cell tumor · mediastinum germ cell tumor · mediastinum germ cell tumour · thymic germ cell tumor · thymic germ cell tumour
Data availability: 9 ClinVar variants.
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › extragonadal germ cell tumor › mediastinal germ cell tumor
Related subtypes (5): central nervous system germ cell tumor, extragonadal germ cell cancer, extragonadal non-dysgerminomatous germ cell tumor, cardiac germ cell tumor, lung germ cell tumor
Subtypes (2): mediastinum teratoma, mediastinal malignant germ cell tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
9 retrieved; paginated sample, class counts are floors:
7 uncertain significance, 1 pathogenic/likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 183726 | NM_000314.8(PTEN):c.406T>C (p.Cys136Arg) | PTEN | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 218342 | NM_000546.6(TP53):c.636del (p.Arg213fs) | TP53 | Pathogenic | reviewed by expert panel |
| 218346 | NM_001099.5(ACP3):c.849CAT[1] (p.Ile284del) | ACP3 | Uncertain significance | no assertion criteria provided |
| 218341 | NM_024535.5(CORO7):c.2772+50C>T | CORO7 | Uncertain significance | no assertion criteria provided |
| 218340 | NM_153487.4(MDGA1):c.2674T>G (p.Phe892Val) | MDGA1 | Uncertain significance | no assertion criteria provided |
| 218344 | NC_012920.1(MT-ND6):m.14372C>A | MT-ND6 | Uncertain significance | no assertion criteria provided |
| 218347 | NM_001346413.3(PCF11):c.3618del (p.Phe1206fs) | PCF11 | Uncertain significance | no assertion criteria provided |
| 218343 | NM_022904.3(RASAL3):c.-5C>G | RASAL3 | Uncertain significance | no assertion criteria provided |
| 218345 | NM_003048.6(SLC9A2):c.2173del (p.Gln725fs) | SLC9A2 | Uncertain significance | no assertion criteria provided |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 38 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Somatic driver evidence (intOGen + CIViC, cohort fanout)
| Gene | intOGen role | Cancer types | CIViC |
|---|---|---|---|
| TP53 | LoF | ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT | CIViC #45 |
| PTEN | LoF | ANGS,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,COADREAD,CSCC,ESCA,GB,GBM,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LUAD,LUSC,MBL,MEL,MT,NSCLC,OVT,PANET,PAST,PRAD,PRCC,PROSTATE,RCC,SCLC,SKCM,SOFT_TISSUE,STAD,UCEC,UCS,WDTC | CIViC #41 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TP53 | Orphanet:1333 | Familial pancreatic carcinoma |
| TP53 | Orphanet:145 | Hereditary breast and/or ovarian cancer syndrome |
| TP53 | Orphanet:1501 | Adrenocortical carcinoma |
| TP53 | Orphanet:210159 | Adult hepatocellular carcinoma |
| TP53 | Orphanet:251576 | Gliosarcoma |
| TP53 | Orphanet:251579 | Giant cell glioblastoma |
| TP53 | Orphanet:251899 | Choroid plexus carcinoma |
| TP53 | Orphanet:2807 | Papilloma of choroid plexus |
| TP53 | Orphanet:293199 | Pleomorphic rhabdomyosarcoma |
| TP53 | Orphanet:3318 | Essential thrombocythemia |
| TP53 | Orphanet:524 | Li-Fraumeni syndrome |
| TP53 | Orphanet:52688 | Myelodysplastic syndrome |
| TP53 | Orphanet:585909 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) |
| TP53 | Orphanet:667662 | Breast implant-associated anaplastic large cell lymphoma |
| TP53 | Orphanet:668 | Osteosarcoma |
| TP53 | Orphanet:67038 | B-cell chronic lymphocytic leukemia |
| TP53 | Orphanet:70573 | Small cell lung cancer |
| TP53 | Orphanet:96253 | Cushing disease |
| TP53 | Orphanet:99756 | Alveolar rhabdomyosarcoma |
| TP53 | Orphanet:99757 | Embryonal rhabdomyosarcoma |
| MT-ND6 | Orphanet:104 | Leber hereditary optic neuropathy |
| MT-ND6 | Orphanet:255210 | Mitochondrial DNA-associated Leigh syndrome |
| MT-ND6 | Orphanet:550 | MELAS |
| MT-ND6 | Orphanet:99718 | Leber plus disease |
| PTEN | Orphanet:109 | Bannayan-Riley-Ruvalcaba syndrome |
| PTEN | Orphanet:137608 | Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome |
| PTEN | Orphanet:145 | Hereditary breast and/or ovarian cancer syndrome |
| PTEN | Orphanet:201 | Cowden syndrome |
| PTEN | Orphanet:210548 | Macrocephaly-intellectual disability-autism syndrome |
| PTEN | Orphanet:2969 | Proteus-like syndrome |
| PTEN | Orphanet:494547 | Squamous cell carcinoma of the hypopharynx |
| PTEN | Orphanet:494550 | Squamous cell carcinoma of the larynx |
| PTEN | Orphanet:500464 | Squamous cell carcinoma of the nasal cavity and paranasal sinuses |
| PTEN | Orphanet:500478 | Squamous cell carcinoma of the oropharynx |
| PTEN | Orphanet:502363 | Squamous cell carcinoma of the oral cavity |
| PTEN | Orphanet:502366 | Squamous cell carcinoma of the lip |
| PTEN | Orphanet:65285 | Lhermitte-Duclos disease |
| PTEN | Orphanet:79076 | Juvenile polyposis of infancy |
Cohort genes → proteins
9 cohort genes, 9 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 9 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| SLC9A2 | HGNC:11072 | ENSG00000115616 | Q9UBY0 | Sodium/hydrogen exchanger 2 | clinvar |
| TP53 | HGNC:11998 | ENSG00000141510 | P04637 | Cellular tumor antigen p53 | clinvar |
| ACP3 | HGNC:125 | ENSG00000014257 | P15309 | Prostatic acid phosphatase | clinvar |
| MDGA1 | HGNC:19267 | ENSG00000112139 | Q8NFP4 | MAM domain-containing glycosylphosphatidylinositol anchor protein 1 | clinvar |
| RASAL3 | HGNC:26129 | ENSG00000105122 | Q86YV0 | RAS protein activator like-3 | clinvar |
| CORO7 | HGNC:26161 | ENSG00000262246 | P57737 | Coronin-7 | clinvar |
| PCF11 | HGNC:30097 | ENSG00000165494 | O94913 | Pre-mRNA cleavage complex 2 protein Pcf11 | clinvar |
| MT-ND6 | HGNC:7462 | ENSG00000198695 | P03923 | NADH-ubiquinone oxidoreductase chain 6 | clinvar |
| PTEN | HGNC:9588 | ENSG00000171862 | P60484 | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| SLC9A2 | Sodium/hydrogen exchanger 2 | Plasma membrane Na(+)/H(+) antiporter. |
| TP53 | Cellular tumor antigen p53 | Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence. |
| ACP3 | Prostatic acid phosphatase | A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. |
| MDGA1 | MAM domain-containing glycosylphosphatidylinositol anchor protein 1 | Required for radial migration of cortical neurons in the superficial layer of the neocortex. |
| RASAL3 | RAS protein activator like-3 | Functions as a Ras GTPase-activating protein. |
| CORO7 | Coronin-7 | F-actin regulator involved in anterograde Golgi to endosome transport: upon ubiquitination via ‘Lys-33’-linked ubiquitin chains by the BCR(KLHL20) E3 ubiquitin ligase complex, interacts with EPS15 and localizes to the trans-Golgi network,… |
| PCF11 | Pre-mRNA cleavage complex 2 protein Pcf11 | Component of pre-mRNA cleavage complex II, which promotes transcription termination by RNA polymerase II. |
| MT-ND6 | NADH-ubiquinone oxidoreductase chain 6 | Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. |
| PTEN | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. |
Protein-family classification
Druggable: 3 · Difficult: 2 · Unknown: 4 · Druggable fraction: 0.33
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Phosphatase | 2 | 18.6× | 0.024 |
| Antibody/Immunoglobulin | 1 | 3.2× | 0.673 |
| Scaffold/PPI | 1 | 1.9× | 0.692 |
| Transcription factor | 1 | 0.9× | 0.847 |
| Other/Unknown | 4 | 0.8× | 0.847 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| SLC9A2 | Other/Unknown | no | NHE-2/4, NaH_exchanger, Cation/H_exchanger_TM | |
| TP53 | Transcription factor | no | p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn | |
| ACP3 | Phosphatase | yes | 3.1.3.2 | His_Pase_clade-2, His_PPase_superfam, Acid_Pase_AS |
| MDGA1 | Antibody/Immunoglobulin | yes | MAM_dom, Ig_sub2, Ig_sub | |
| RASAL3 | Other/Unknown | no | C2_dom, RasGAP_dom, Rho_GTPase_activation_prot | |
| CORO7 | Scaffold/PPI | no | WD40_rpt, DUF1899, Coronin | |
| PCF11 | Other/Unknown | no | CID_dom, ENTH_VHS, Pcf11_Clp1-ID | |
| MT-ND6 | Other/Unknown | no | NADH_UbQ/plastoQ_OxRdtase_su6, ComplexI_Subunit6 | |
| PTEN | Phosphatase | yes | 3.1.3.16 | Tyr_Pase_dom, Tyr_Pase_cat, Tensin_C2-dom |
Expression context
Cohort genes with no expression data: 0.
7 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 9 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| granulocyte | 2 |
| calcaneal tendon | 2 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| mucosa of transverse colon | 1 |
| rectum | 1 |
| ganglionic eminence | 1 |
| tendon of biceps brachii | 1 |
| ventricular zone | 1 |
| esophagus squamous epithelium | 1 |
| prostate gland | 1 |
| tongue squamous epithelium | 1 |
| cardiac muscle of right atrium | 1 |
| cerebellar cortex | 1 |
| cerebellar hemisphere | 1 |
| lymph node | 1 |
| spleen | 1 |
| blood | 1 |
| bone marrow | 1 |
| skin of abdomen | 1 |
| skin of leg | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| SLC9A2 | 144 | broad | marker | rectum, male germ line stem cell (sensu Vertebrata) in testis, mucosa of transverse colon |
| TP53 | 223 | ubiquitous | marker | ventricular zone, ganglionic eminence, tendon of biceps brachii |
| ACP3 | 210 | broad | marker | prostate gland, tongue squamous epithelium, esophagus squamous epithelium |
| MDGA1 | 223 | broad | yes | cerebellar hemisphere, cardiac muscle of right atrium, cerebellar cortex |
| RASAL3 | 217 | broad | marker | granulocyte, spleen, lymph node |
| CORO7 | 138 | ubiquitous | yes | granulocyte, bone marrow, blood |
| PCF11 | 260 | ubiquitous | marker | calcaneal tendon, skin of abdomen, skin of leg |
| MT-ND6 | 134 | ubiquitous | marker | mucosa of stomach, left uterine tube, right uterine tube |
| PTEN | 256 | ubiquitous | marker | sperm, endothelial cell, calcaneal tendon |
Protein interactions among cohort
Intra-cohort edges: 1.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| TP53 | 22,736 |
| PTEN | 11,626 |
| PCF11 | 2,439 |
| MDGA1 | 1,526 |
| RASAL3 | 1,417 |
| ACP3 | 1,224 |
| MT-ND6 | 1,208 |
| SLC9A2 | 1,115 |
| CORO7 | 640 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| PTEN | TP53 | string_interaction |
Structural data
PDB: 7 · AlphaFold-only: 2 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TP53 | P04637 | 313 |
| ACP3 | P15309 | 17 |
| PTEN | P60484 | 12 |
| MT-ND6 | P03923 | 5 |
| MDGA1 | Q8NFP4 | 3 |
| CORO7 | P57737 | 1 |
| PCF11 | O94913 | 1 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| SLC9A2 | Q9UBY0 | 66.40 |
| RASAL3 | Q86YV0 | 66.34 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 74. Enrichment computed across 9 evidence-associated genes (8 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Loss of function of TP53 in cancer due to loss of tetramerization ability | 1 | 1427.5× | 0.020 | TP53 |
| PTEN Loss of Function in Cancer | 1 | 713.8× | 0.020 | PTEN |
| Regulation of TP53 Expression | 1 | 713.8× | 0.020 | TP53 |
| Ovarian tumor domain proteases | 2 | 69.6× | 0.020 | TP53, PTEN |
| Regulation of PTEN gene transcription | 2 | 44.6× | 0.020 | TP53, PTEN |
| TP53 Regulates Metabolic Genes | 2 | 32.4× | 0.020 | TP53, PTEN |
| Transcriptional activation of cell cycle inhibitor p21 | 1 | 356.9× | 0.030 | TP53 |
| Activation of NOXA and translocation to mitochondria | 1 | 237.9× | 0.036 | TP53 |
| RUNX3 regulates CDKN1A transcription | 1 | 203.9× | 0.036 | TP53 |
| Sodium/Proton exchangers | 1 | 158.6× | 0.036 | SLC9A2 |
| PI5P Regulates TP53 Acetylation | 1 | 158.6× | 0.036 | TP53 |
| Activation of PUMA and translocation to mitochondria | 1 | 142.8× | 0.036 | TP53 |
| Regulation of PTEN mRNA translation | 1 | 142.8× | 0.036 | PTEN |
| Regulation of PTEN localization | 1 | 129.8× | 0.036 | PTEN |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 1 | 119.0× | 0.036 | TP53 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 1 | 119.0× | 0.036 | TP53 |
| Urea cycle | 1 | 109.8× | 0.036 | TP53 |
| Regulation of TP53 Activity through Association with Co-factors | 1 | 102.0× | 0.036 | TP53 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 1 | 95.2× | 0.036 | TP53 |
| Stabilization of p53 | 1 | 95.2× | 0.036 | TP53 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 1 | 89.2× | 0.036 | TP53 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 1 | 84.0× | 0.036 | TP53 |
| Zygotic genome activation (ZGA) | 1 | 84.0× | 0.036 | TP53 |
| Regulation of NF-kappa B signaling | 1 | 79.3× | 0.036 | TP53 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 1 | 75.1× | 0.036 | TP53 |
| SUMOylation of transcription factors | 1 | 71.4× | 0.036 | TP53 |
| Processing of Intronless Pre-mRNAs | 1 | 71.4× | 0.036 | PCF11 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 1 | 68.0× | 0.036 | TP53 |
| Regulation of TP53 Activity through Methylation | 1 | 68.0× | 0.036 | TP53 |
| Ub-specific processing proteases | 2 | 13.3× | 0.036 | TP53, PTEN |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| prepulse inhibition | 2 | 249.7× | 0.006 | MDGA1, PTEN |
| negative regulation of helicase activity | 1 | 1872.4× | 0.020 | TP53 |
| cellular response to actinomycin D | 1 | 1872.4× | 0.020 | TP53 |
| regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 1872.4× | 0.020 | TP53 |
| negative regulation of G1 to G0 transition | 1 | 1872.4× | 0.020 | TP53 |
| positive regulation of mitochondrial membrane permeability | 1 | 936.2× | 0.020 | TP53 |
| oligodendrocyte apoptotic process | 1 | 936.2× | 0.020 | TP53 |
| negative regulation of glucose catabolic process to lactate via pyruvate | 1 | 936.2× | 0.020 | TP53 |
| negative regulation of pentose-phosphate shunt | 1 | 936.2× | 0.020 | TP53 |
| negative regulation of synaptic vesicle clustering | 1 | 936.2× | 0.020 | PTEN |
| obsolete homolactic fermentation | 1 | 624.1× | 0.020 | TP53 |
| negative regulation of keratinocyte migration | 1 | 624.1× | 0.020 | PTEN |
| positive regulation of adenosine receptor signaling pathway | 1 | 624.1× | 0.020 | ACP3 |
| signal transduction by p53 class mediator | 1 | 624.1× | 0.020 | TP53 |
| negative regulation of miRNA processing | 1 | 624.1× | 0.020 | TP53 |
| intrinsic apoptotic signaling pathway in response to hypoxia | 1 | 624.1× | 0.020 | TP53 |
| regulation of fibroblast apoptotic process | 1 | 624.1× | 0.020 | TP53 |
| T cell proliferation involved in immune response | 1 | 468.1× | 0.020 | TP53 |
| thiamine metabolic process | 1 | 468.1× | 0.020 | ACP3 |
| rhythmic synaptic transmission | 1 | 468.1× | 0.020 | PTEN |
| positive regulation of programmed necrotic cell death | 1 | 468.1× | 0.020 | TP53 |
| oxidative stress-induced premature senescence | 1 | 468.1× | 0.020 | TP53 |
| regulation of synaptic membrane adhesion | 1 | 468.1× | 0.020 | MDGA1 |
| B cell lineage commitment | 1 | 374.5× | 0.020 | TP53 |
| T cell lineage commitment | 1 | 374.5× | 0.020 | TP53 |
| mRNA transcription | 1 | 374.5× | 0.020 | TP53 |
| positive regulation of RNA polymerase II transcription preinitiation complex assembly | 1 | 374.5× | 0.020 | TP53 |
| positive regulation of thymocyte apoptotic process | 1 | 374.5× | 0.020 | TP53 |
| cellular response to UV-C | 1 | 374.5× | 0.020 | TP53 |
| central nervous system myelin maintenance | 1 | 312.1× | 0.020 | PTEN |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 2 · Undrugged: 7
Druggability breadth: 5 of 9 evidence-associated genes (56%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| TP53 | NITROFURANTOIN |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TP53 | 196 | 4 |
| SLC9A2 | 3 | 2 |
| ACP3 | 0 | 0 |
| MDGA1 | 0 | 0 |
| RASAL3 | 0 | 0 |
| CORO7 | 0 | 0 |
| PCF11 | 0 | 0 |
| MT-ND6 | 0 | 0 |
| PTEN | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| NITROFURANTOIN | 4 | TP53 |
| DIOSMIN | 4 | TP53 |
| VERTEPORFIN | 4 | TP53 |
| CANDESARTAN CILEXETIL | 4 | TP53 |
| DIENESTROL | 4 | TP53 |
| CLOTRIMAZOLE | 4 | TP53 |
| COLCHICINE | 4 | TP53 |
| NABUMETONE | 4 | TP53 |
| SALMETEROL XINAFOATE | 4 | TP53 |
| AMIODARONE HYDROCHLORIDE | 4 | TP53 |
| FURAZOLIDONE | 4 | TP53 |
| AMOXAPINE | 4 | TP53 |
| RALOXIFENE HYDROCHLORIDE | 4 | TP53 |
| NICARDIPINE HYDROCHLORIDE | 4 | TP53 |
| SULCONAZOLE NITRATE | 4 | TP53 |
| PYRITHIONE ZINC | 4 | TP53 |
| LACTIC ACID | 4 | TP53 |
| OXYMETHOLONE | 4 | TP53 |
| CHLOROXINE | 4 | TP53 |
| PROPIOLACTONE | 4 | TP53 |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | TP53 |
| PHENYL AMINOSALICYLATE | 4 | TP53 |
| THIORIDAZINE HYDROCHLORIDE | 4 | TP53 |
| AMITRIPTYLINE HYDROCHLORIDE | 4 | TP53 |
| ETHOPROPAZINE HYDROCHLORIDE | 4 | TP53 |
| MECHLORETHAMINE HYDROCHLORIDE | 4 | TP53 |
| ECONAZOLE NITRATE | 4 | TP53 |
| TRIFLUPROMAZINE HYDROCHLORIDE | 4 | TP53 |
| PROCHLORPERAZINE EDISYLATE | 4 | TP53 |
| DEQUALINIUM CHLORIDE | 4 | TP53 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 2.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| TP53 | 869 | Binding:775, ADMET:83, Functional:10, Toxicity:1 |
| SLC9A2 | 10 | Binding:8, Functional:2 |
| PTEN | 8 | Binding:8 |
| ACP3 | 6 | Binding:6 |
| MT-ND6 | 4 | Binding:4 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| ACP3 | 3.1.3.2 | acid phosphatase |
| PTEN | 3.1.3.16, 3.1.3.67 | protein-serine/threonine phosphatase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| TP53 | 869 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 9; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Drug repurposing candidates
30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| NITROFURANTOIN | 4 | TP53 |
| DIOSMIN | 4 | TP53 |
| VERTEPORFIN | 4 | TP53 |
| CANDESARTAN CILEXETIL | 4 | TP53 |
| DIENESTROL | 4 | TP53 |
| CLOTRIMAZOLE | 4 | TP53 |
| COLCHICINE | 4 | TP53 |
| NABUMETONE | 4 | TP53 |
| SALMETEROL XINAFOATE | 4 | TP53 |
| AMIODARONE HYDROCHLORIDE | 4 | TP53 |
| FURAZOLIDONE | 4 | TP53 |
| AMOXAPINE | 4 | TP53 |
| RALOXIFENE HYDROCHLORIDE | 4 | TP53 |
| NICARDIPINE HYDROCHLORIDE | 4 | TP53 |
| SULCONAZOLE NITRATE | 4 | TP53 |
| PYRITHIONE ZINC | 4 | TP53 |
| LACTIC ACID | 4 | TP53 |
| OXYMETHOLONE | 4 | TP53 |
| CHLOROXINE | 4 | TP53 |
| PROPIOLACTONE | 4 | TP53 |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | TP53 |
| PHENYL AMINOSALICYLATE | 4 | TP53 |
| THIORIDAZINE HYDROCHLORIDE | 4 | TP53 |
| AMITRIPTYLINE HYDROCHLORIDE | 4 | TP53 |
| ETHOPROPAZINE HYDROCHLORIDE | 4 | TP53 |
| MECHLORETHAMINE HYDROCHLORIDE | 4 | TP53 |
| ECONAZOLE NITRATE | 4 | TP53 |
| TRIFLUPROMAZINE HYDROCHLORIDE | 4 | TP53 |
| PROCHLORPERAZINE EDISYLATE | 4 | TP53 |
| DEQUALINIUM CHLORIDE | 4 | TP53 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | TP53 |
| B | Phased (≥1) drug, not yet approved | 1 | SLC9A2 |
| C | Druggable family + PDB, no drug | 3 | ACP3, MDGA1, PTEN |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 4 | RASAL3, CORO7, PCF11, MT-ND6 |
Undrugged target profiles
7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| PTEN | 8 | TP53 |
| ACP3 | 6 | — |
| MDGA1 | 0 | — |
| RASAL3 | 0 | — |
| CORO7 | 0 | — |
| PCF11 | 0 | — |
| MT-ND6 | 4 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.